Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01702519 · ClinicalTrials.gov registry record · Phase 1
A Pharmacokinetic Evaluation of Two Nicotine Patches in Smokers
A Phase 1 study of Smoking, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT01702519 is a Phase 1 study of Smoking that has completed, run by GlaxoSmithKline. The registered enrollment target is 40 participants, below the 455-participant average among 123 other Smoking trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01702519, a Phase 1 study of Smoking, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
Bioequivalence study to confirm that a NTS with a polyisobutylene (PIB) adhesive from an alternative supplier delivers the same nicotine blood profile as that of the currently approved NTS with a polyisobutylene adhesive from the current supplier.
Conditions Studied
Interventions
- DRUG nicotine
Study Locations (1)
Nebraska
- Celerion NEBRASKA - Lincoln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2012-03 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01702519
The ClinicalTrials.gov registry entry for NCT01702519 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 455-participant average among 123 other Smoking trials with a reported enrollment target (91% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Smoking appearing as the primary indexed condition, and to 1 intervention - of which nicotine is the first listed.
NCT01702519 reports 1 study location spanning 1 distinct geographic area - top geographies include Nebraska.
Frequently Asked Questions
What is clinical trial NCT01702519 about?
NCT01702519 is a clinical study titled "A Pharmacokinetic Evaluation of Two Nicotine Patches in Smokers". Bioequivalence study to confirm that a NTS with a polyisobutylene (PIB) adhesive from an alternative supplier delivers the same nicotine blood profile as that of the currently approved NTS with a polyisobutylene adhesive from the current supplier.
What is the current status of trial NCT01702519?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2012-03. Estimated completion is 2012-03.
What conditions does trial NCT01702519 study?
This clinical trial studies the following conditions: Smoking.
What interventions are being tested in trial NCT01702519?
The interventions under investigation include: nicotine (DRUG).
Who is sponsoring clinical trial NCT01702519?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01702519 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Smoking Cessation for Depressed Smokers
ACTIVE NOT RECRUITING · Phase 1
-
Galantamine Effects on Nicotine Responses in Smokers
COMPLETED · Phase 1
-
Group Counseling for Smoking Cessation
COMPLETED · Phase 1
-
Integrating Financial Coaching and Smoking Cessation Coaching
RECRUITING · Phase 3
-
Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies
RECRUITING
-
Modifying Progesterone and Estradiol Levels to Prevent Postpartum Cigarette Smoking Relapse and Reduce Secondhand Smoke Exposure in Infants and Children
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.